FlixBus parent company Flix is joining forces with international non-profit organisation DKMS, which is dedicated to saving the lives of patients with blood cancer and blood disorders, in a long-term partnership to raise awareness and drive stem cell donor registration across six countries.
Through the collaboration, entitled ‘Your journey could save a life,’ DKMS and Flix say they are aiming to make registration as a potential stem cell donor as accessible and seamless as possible. Travellers using on-board WiFi on FlixBus in the United Kingdom, Germany, Poland, Chile and the United States, as well as its FlixTrain services, will be guided to a dedicated landing page where they can begin the registration process with just a few clicks.
The operator highlights that every 27 seconds, someone in the world is diagnosed with blood cancer or a severe blood disorder, whilst in the UK, a new blood cancer diagnosis occurs every 14 minutes, and that although around 30% of patients may find a matching stem cell donor within their family, the remainder rely on unrelated donors, many of whom never find a match due to underrepresentation in donor registers, something which DKMS is working to rectify.
Flix says the campaign leverages its international reach and digital infrastructure to promote awareness and action in the six participating countries. “Every journey has the potential to change lives for those who travel, and for those waiting for a second chance at life,” said Global CEO of DKMS Elke Neujahr. “By partnering with Flix, we’re turning mobility into meaningful impact.” DKMS UK Managing Director Peter McCleave added: “Through this partnership with Flix, we are reaching people in everyday moments and showing them how easy it is to take the first step toward saving a life. It’s a simple act that can make a real difference, not only for patients here in the UK but around the world.” CEO of Flix André Schwämmlein commented: “This collaboration shows how technology, mobility and purpose can come together. Flix connects people every day across borders, and now we’re helping connect potential lifesavers with patients around the world.”
